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Abstract
Background: Patients who receive an abnormal cancer screen-
ing result require follow-up for diagnostic testing, but the time to
follow-up varies across patients and practices.
Methods:Weused a simulation study to estimate the change in
lifetime screening beneﬁts when time to follow-up for breast,
cervical, and colorectal cancers was increased. Estimates were
based on four independently developedmicrosimulationmodels
that each simulated the life course of adults eligible for breast
(women ages 50–74 years), cervical (women ages 21–65 years),
or colorectal (adults ages 50–75 years) cancer screening. We
assumed screening based on biennial mammography for breast
cancer, triennial Papanicolaou testing for cervical cancer, and
annual fecal immunochemical testing for colorectal cancer. For
each cancer type, we simulated diagnostic testing immediately
and at 3, 6, and 12 months after an abnormal screening exam.
Results: We found declines in screening beneﬁt with longer
times todiagnostic testing, particularly for breast cancer screening.
Compared to immediate diagnostic testing, testing at 3 months
resulted in reduced screening beneﬁt, with fewer undiscounted
life years gained per 1,000 screened (breast: 17.3%, cervical: 0.8%,
colorectal: 2.0% and 2.7%, from two colorectal cancer models),
fewer cancers prevented (cervical: 1.4% fewer, colorectal: 0.5%
and 1.7% fewer, respectively), and, for breast and colorectal
cancer, a less favorable stage distribution.
Conclusions: Longer times to diagnostic testing after an abnor-
mal screening test can decrease screening effectiveness, but the
impact varies substantially by cancer type.
Impact:Understanding the impact of time to diagnostic testing
on screening effectiveness can help inform quality improvement
efforts. Cancer Epidemiol Biomarkers Prev; 27(2); 158–64. 2017 AACR.
Introduction
Cancer screening is a multistep process of care that often
requires patients to navigate multiple health facilities and spe-
cialties (1, 2), requiring coordination and potentially lengthy
times to complete a screening episode. Tosteson and colleagues
(2015) demonstrated variability in the time to initial follow-up of
screen-positive results across patients, cancer types, and health
care systems (3), but the clinical implications of this substantial
variationareunknown.Although the vastmajority ofwomenwith
an abnormal screening mammogram took the next step toward
diagnosis within weeks of the screening mammogram, 4.4% did
not complete the next step in a timely manner (ref. 3; within 3
months for an incomplete exam or an exam with suspicious
ﬁndings; within 9 months for an exam with probably benign
ﬁndings). Among women screened for cervical cancer using a Pap
test, 45% with an abnormal result [atypical squamous cells of
undetermined signiﬁcance (ASC-US) with HPV-positive result or
worse] received recommended diagnostic assessment with either
repeat testing or colposcopy/biopsy within 3 months (3). Among
adults screened for colorectal cancer using a fecal test, 68%with a
positive result indicating detection of occult blood received diag-
nostic assessment (colonoscopy) within 3 months (3).
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Longer time to clinical follow-up and subsequent diagnostic
testing theoretically leads to an increased risk for disease progres-
sion, but it is unclear whether the observed variability in time to
diagnostic testing hasmeaningful effects on clinical outcomes and
how effects might differ by cancer type. Data needed to directly
estimate the effects of time from an abnormal screening result to
diagnostic assessment on clinical outcomes are scarce. A random-
ized study would be unethical and observational studies exam-
ining the effect of time to diagnostic assessment on short-term
outcomes, such as cancers detected at screening and cancer stage at
detection, require a large screened population andmay be biased
because of nonrandom selection of time to diagnostic testing. For
example, abnormal screening tests may be more rapidly assessed
when patients have a family history of cancer, develop symptoms,
or have other risk factors.
Microsimulation models can be used to simulate outcomes
that may not be feasible to study with randomized controlled
trials and are not subject to selection bias (4). In this article, we use
microsimulation models to estimate the impact of the length of
time from an abnormal screening test to diagnostic evaluation on
long-term health outcomes across three cancers.
Materials and Methods
We used four independently developed models to simulate
detection of and death from breast, cervical, and colorectal
cancers. Each of these models is supported by the National Can-
cer Institute's Cancer Intervention and Surveillance Modeling
Network (CISNET; ref. 5).
Models
Each model describes the disease processes in the absence of
screening or any other intervention. In all models, individuals
begin in a disease-free state and potentially transition to pre-
clinical (asymptomatic) cancer. From the preclinical cancer
state, individuals may transition to a clinical (symptomatic)
cancer state. The breast cancer model allows women to tran-
sition from the preclinical cancer state back to the disease-free
state, due to regression of ductal carcinoma in situ (DCIS) and
some small invasive cancers. Cervical and colorectal cancer
models include one or more precursor lesion states that precede
preclinical cancer. The cervical cancer model allows women to
transition from precursor states back to the disease-free state,
whereas the colorectal cancer models do not allow regression of
precursor lesions.
For each cancer, we simulated outcomes with and without
screening and under different screening assumptions. In the
absence of screening, cancer is detected when an individual
transitions into the (symptomatic) clinical cancer state. Screening
can beneﬁt patients through detection of preclinical cancer, which
may result in detection at an earlier andmore treatable stage than
clinically detected cancer. For cancers with a precursor lesion,
screening may beneﬁt patients by detecting and removing lesions
that might otherwise progress to symptomatic cancer, thereby
reducing cancer incidence. In the remainder of this section, we
outline each of the four models. Detailed model descriptions are
available online at https://resources.cisnet.cancer.gov/registry.
The University of Wisconsin Breast Cancer Simulation Model
simulates breast cancer incidence and mortality according to
estrogen receptor (ER) and HER2-speciﬁc status in the U.S.
population over time (6, 7). The probability that a woman will
develop breast cancer is informed by an age-period-cohortmodel,
reﬂecting breast cancer incidence in the absence of screening and
accounts for population trends in risk factors and screening
utilization (8). Disease progression varies randomly across
individuals.
The breast cancer model simulates mammographic sensitivity
(the probability of detecting cancer when it is present) as a
function of lesion size, and was calibrated to accurately predict
mammography performance data by age, screening round, and
breast density (9). For example, sensitivity ranges from 0.94 for
women 65 years and older with fatty (BI-RADS 1) breasts to 0.75
for women from 40 to 49 years old with dense (BI-RADS 4)
breasts; speciﬁcity ranges from 0.95 for women 65 years and older
with fatty breasts to 0.85 for women 40 to 49 years old with
heterogeneously dense (BI-RADS 3) breasts. Breast biopsy is
assumed to diagnose breast cancer with perfect accuracy. Women
diagnosed with breast cancer are assumed to receive the most
effective treatment currently available based on their simulated
age, stage, and ER/HER2 status at diagnosis. Treatment effective-
ness is based on clinical trials and is modeled as an increase in the
proportion cured relative to ER/HER2-speciﬁc survival in the
absence of therapy (10).
The Harvard cervical cancer model simulates human papillo-
mavirus (HPV)-induced cervical carcinogenesis (11, 12). For each
woman, the model simulates the risk of HPV infection, develop-
ment, and regression of precursor lesions [i.e., cervical intrae-
pithelial neoplasia, grade 2 (CIN2) or grade 3 (CIN3)], and onset
and progression of invasive cancer (i.e., local, regional, and
distant disease). Precursor lesions may be associated with either
nononcogenic or oncogenic HPV; only those associated with
oncogenic infections can progress to cancer. The probability of
transition between precursor and cancer states can vary by age,
HPV type, duration of infection or lesion status, and a woman's
history of prior HPV infection and CIN treatment.
The cervical cancer model simulates outcomes from Pap
smear–based screening. Pap test sensitivity to detect high-grade
CIN2 ormore advanced lesions is 0.70; speciﬁcity is 0.91.Women
with Pap results of low-grade squamous intraepithelial lesions
(LSIL) or worse are referred to undergo diagnostic colposcopy/
biopsy, whereas women with ASC-US undergo HPV testing and
all HPV-positive women are referred to diagnostic colposcopy/
biopsy. Colposcopy/biopsy is assumed to identify preclinical
cervical cancer and precursor lesions with perfect accuracy, and
women are assumed to undergo treatment immediately upon
diagnosis of CIN2 or more advanced disease.
We used two colorectal cancer models: ColoRectal Cancer
Simulated Population model for Incidence and Natural history
(CRC-SPIN; ref. 13) and MIcrosimulation SCcreening ANalysis-
ColoRectal Cancer (MISCAN-Colon; ref. 14). Both models
describe the natural history of colorectal cancer based on the
adenoma–carcinoma process (15, 16). Individuals begin in a
disease-free state andmay progressively transition to an adenoma
state, a preclinical cancer state, and a clinically detected cancer
state. Disease progression depends systematically on age and sex,
and varies randomly across individuals. The two models have
different assumptions about the time from adenoma initiation
to preclinical cancer ("dwell time") and the time from
preclinical cancer initiation to symptomatic detection ("sojourn
time"; ref. 17). Compared with CRC-SPIN, the MISCAN-Colon
model assumes a shorter mean dwell time and a longer mean
sojourn time.
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Both colorectal cancer models simulate outcomes from fecal
immunochemical testing (FIT). The person-level speciﬁcity of FIT
(for individuals with neither adenomas nor preclinical cancer) is
0.964; person-level sensitivity, based on the most advanced
lesion, is 0.076 for 1 to 9 mm adenomas, 0.238 for adenomas
that are 10 mm or larger, and 0.738 for preclinical cancers
(18). Both models use person-level FIT speciﬁcity directly. The
CRC-SPIN model uses person-level FIT sensitivity directly,
simulating positive FIT results based on an individual's most
advanced lesion. The MISCAN model uses lesion-speciﬁc sensi-
tivity calibrated to match person-level sensitivity. Both colorectal
cancer models simulate imperfect colonoscopy, so that screen-
detected lesions may be missed at diagnostic evaluation. Survival
after colorectal cancer diagnosis is based on estimates from SEER
data for individuals diagnosed in 2003, the most recent year with
longer-term survival information (19).
Simulated cohorts
For each cancer type, we simulated an unscreened cohort and
then simulated screening regimens under four scenarios: imme-
diate diagnostic testing of abnormal screening result, and
diagnostic testing 3, 6, and 12 months after an abnormal
screening result. Immediate diagnostic testing after a positive
screening test, whereas unrealistic, reﬂects the maximum ben-
eﬁt achievable from recommended screening. We standardized
simulated cohorts so that screening is initiated in 2015 across
all cancers because of the potential impact of year of detection
on both overall and cancer-speciﬁc mortality. Therefore, the
breast and colorectal cancer models simulated individuals born
in 1965, and the cervical cancer model simulated individuals
born in 1994.
Simulated screening regimens
Screening was simulated according to regimens that are
consistent with current United States Preventive Services Task
Force (USPSTF) recommendations (Table 1; refs. 20–22). To
isolate the effect of time to diagnostic testing, we simulated
perfect adherence to screening regimens, and varied only the
time between a positive result and subsequent diagnostic
testing to rule-in or rule-out disease.
Outcomes
We calculated three measures of lifetime screening beneﬁt,
from the age of screening initiation through age 100 years: (i)
cancers prevented, relative to no screening; (ii) cancer stage
distribution at diagnosis; and (iii) undiscounted life years gained
(LYG), relative to no screening. LYG were estimated as the dif-
ference in the simulated number of person-years for screened
versus unscreened cohorts. We also estimated two relative risks
(RRs) comparing outcomes with diagnostic testing at 3, 6, and
12 months relative to immediate diagnostic testing: the lifetime
RR of cancer diagnosis and the RR of cancer diagnosis at a late
stage (distant or regional, or stage 3 or 4) among those diagnosed
with cancer.
Results
Screening increased the incidence of detected breast cancer,
and decreased the incidence of cervical and colorectal cancers
(Table 2). The breast cancer model predicted that screening
would increase lifetime cancer incidence by 2.6 per 100 persons
screened, with slightly smaller increases in cancer incidence as
length of time to diagnostic testing increased. The cervical and
colorectal cancer models predicted that screening would
decrease lifetime cancer incidence, with small decrements in
beneﬁt as length of time to diagnostic testing increased. Com-
pared to immediate diagnostic testing, testing at 3 months
would result in 1.4% fewer cervical cancers prevented, and
1.7% (CRC-SPIN) and 0.5% (MISCAN-Colon) fewer colorectal
cancers prevented. The RR of a lifetime cancer diagnosis among
those screened with diagnostic testing at 3 months relative to
immediate diagnosis was 1.00 for breast cancer, 1.11 for
cervical cancer, and 1.01 (CRC-SPIN) or 1.02 (MISCAN-Colon)
for colorectal cancer; at 12 months, the RRs were 0.98 for breast,
1.36 for cervical cancer, and 1.05 for colorectal cancer (both
CRC-SPIN and MISCAN-Colon).
All models predicted that screening would reduce the propor-
tion of late-stage cancers relative to no screening (Table 3). For the
most part, longer times to diagnostic testing resulted in increases
in diagnosis of late-stage disease. For breast cancer, screening with
immediate diagnostic testing detected 24% more cancers overall
relative to no screening, speciﬁcally,moreDCIS (24.5%of cancers
diagnosed vs. 5.3%, respectively) and less late-stage disease
(26.7% vs. 46.6%). Cervical and colorectal cancer screening with
immediate diagnostic testing resulted in declines in both cancer
incidence and the percent of cancers detected at a late stage.
Among individuals diagnosed with cancer, the RR of a late-stage
detection with diagnostic testing at 3 months relative to imme-
diate testing was 1.08 for breast cancer, 0.99 for cervical cancer,
and 1.03 for colorectal cancer (both CRC-SPIN and MISCAN-
Colon); the RR of late-stage diagnosis with testing at 12 months
relative to immediate testing was 1.26 (breast), 0.98 (cervical),
1.12 (CRC-SPIN), and 1.11 (MISCAN-Colon).
Table 1. Screening regimens that were simulated for each cancer site by age
group and periodicity
Breast Cervical Colorectal
Test Digital
mammogram
Papanicolaou
(Pap)
Fecal
immunochemical
test (FIT)
Interval 2 years 3 years 1 year
Screening ages 50–74 years 21–65a years 50–75 years
aScreening ends at age 65 for women who have not had abnormal screening
results over the past 10 years; otherwise, screening continues past age 65 until
there are three consecutive normal results.
Table 2. Predicted effect of screening and time to diagnostic testing of screening abnormalities on lifetime cancer incidence per 100 screened
Change in cancer incidence with screening
Model Unscreened Immediate diagnosis 3 months 6 months 12 months
Breast 11.0 2.6 (24.0%) 2.6 (23.5%) 2.5 (22.9%) 2.4 (21.7%)
Cervical 2.2 1.9 (88.9%) 1.9 (87.6%) 1.9 (86.6%) 1.8 (84.8%)
CRC-SPIN 7.2 5.3 (73.9%) 5.3 (73.6%) 5.3 (73.3%) 5.2 (72.5%)
MISCAN-Colon 6.6 3.1 (46.9%) 3.1 (46.1%) 3.0 (45.4%) 2.9 (44.2%)
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LYG incorporates the impact of time to screening on mortality
through cancer prevention and stage shift. All fourmodels predict
decrements in LYG with lengthening time to diagnostic testing,
relative to the potential maximum with immediate testing
(Table 4), with the largest losses for breast cancer.With a 3-month
time to diagnostic testing, the estimated loss of potential
LYG was equal to 17.3% for breast cancer, 0.8% for cervical
cancer, and 2.0% (CRC-SPIN) and 2.7% (MISCAN-Colon) for
colorectal cancer.
Discussion
Theoretically, screening beneﬁt is maximized when diagnostic
testing occurs immediately, on the same day as the receipt of a
positive screening test. We examined the relative beneﬁt of
screeningwhen diagnostic testing occurred at 3, 6, and 12months
after an abnormal screening result compared to this theoretical
maximum. Longer time to diagnostic testing reduced the beneﬁt
of screening, resulting in higher lifetime cancer incidence (cervical
and colorectal), later stage at diagnosis (breast and colorectal),
and fewer LYG (all cancers).
The effects of time to diagnostic testing on reduction in screen-
ing beneﬁt varied across cancers, in ways that are consistent with
differences in their natural history and the action of screening.
Breast cancer screening focuses on early detection of malignant
lesions (20, 23); our results indicate that failure to promptly
diagnose and treat malignant breast lesions would have
substantial impacts on screening effectiveness. Longer time to
diagnostic assessment of abnormal mammograms resulted in
more late-stage disease and fewer LYG via screening. Across the
three cancerswe simulated, breast cancer demonstrated the largest
loss in LYG as the time to diagnostic testing increased.
In contrast to breast cancer screening, cervical and colorectal
cancer screening can result in detection and removal of pre-
cursor lesions. Longer time to diagnostic assessment reduced
cervical and colorectal cancer screening effectiveness, but with
modest effects compared with breast cancer. Both cervical and
colorectal cancers are characterized by slowly progressing pre-
cursor lesions, providing a long window of opportunity for
disease prevention.
Even with longer time to diagnostic testing, our study suggests
that screening detected most disease at an earlier and more
treatable stage. Longer times to diagnostic testing had the smallest
impact on disease-stage distribution for cervical cancer. Cervical
cancer arises fromprecursor lesions thatmay occur relatively early
in life, and some lesions may regress. The effect of time to
diagnostic assessment on stage at cervical cancer detection was
counter-intuitive; the proportion of late-stage cervical cancers
declined with longer time to assessment. Over this 12-month
timeframe, the cervical model simulated transition of more pre-
cursor lesions into early-stage disease than transitionof preclinical
cancers from early- to late-stage disease. Importantly, the absolute
incidence of late-stage cervical disease increasedwith longer times
to diagnostic testing.
Table 3. Predicted effect of screening and time to diagnostic assessment of abnormal screening tests on cancer stage distribution at detection (percent in each
stage), among those diagnosed with cancer (shown as the incidence per 100 screened)
Time to diagnosis
Model Unscreened Immediate 3 months 6 months 12 months
Breast
Incidence per 100 11.00 13.65 13.58 13.52 13.39
% DCIS 5.3 24.5 21.8 19.2 17.0
% Local 48.1 48.9 49.5 50.1 49.5
% Regional 39.7 23.1 25.0 26.8 29.2
% Distant 7.0 3.5 3.7 3.9 4.2
Cervical
Incidence per 100 2.18 0.24 0.27 0.29 0.33
% Local 51.3 67.1 67.5 67.6 67.9
% Regional 38.3 26.7 26.5 26.5 26.3
% Distant 10.4 6.2 6.0 5.9 5.8
CRC-SPIN
Incidence per 100 7.17 1.87 1.89 1.92 1.97
% Stage 1 17.8 39.4 37.9 36.1 32.6
% Stage 2 36.2 28.5 29.1 30.0 31.3
% Stage 3 26.7 19.5 20.0 20.6 21.7
% Stage 4 19.2 12.6 13.1 13.4 14.4
MISCAN-Colon
Incidence per 100 6.63 3.52 3.58 3.62 3.70
% Stage 1 17.6 51.7 49.9 48.6 46.0
% Stage 2 33.8 25.8 26.9 27.6 29.1
% Stage 3 24.1 13.3 13.8 14.3 15.0
% Stage 4 24.5 9.1 9.4 9.5 9.9
NOTE: Small variations in numbers are shown in Tables 3 and 4 reﬂect rounding.
Table 4. Predicted LYG per 1,000 screened by time to diagnostic testing and decrement in LYG relative to immediate diagnostic testing
LYG per 1,000 screened (and percent change) relative to immediate diagnosis
Model Immediate 3 months 6 months 12 months
Breast 101.6 84.1 (17.3%) 66.1 (34.9%) 41.0 (59.6%)
Cervical 281.7 279.5 (0.8%) 277.6 (1.4%) 273.8 (2.8%)
CRC-SPIN 249.8 244.8 (2.0%) 239.7 (4.1%) 230.2 (7.8%)
MISCAN-Colon 233.7 227.3 (2.7%) 222.7 (4.7%) 213.7 (8.6%)
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Inclusion of two colorectal cancer models provides an oppor-
tunity to compare results across models with different assump-
tions. The CRC-SPIN model simulates a longer adenoma dwell
time on average than the MISCAN-Colon model, and predicted a
slightly smaller effect of time to diagnostic testing on cancer
incidence than the MISCAN-Colon model. The MISCAN-Colon
model simulates a longer sojourn time than theCRC-SPINmodel,
and predicted slightly smaller effect of time to diagnostic testing
on cancer stage than the CRC-SPIN model. Despite these differ-
ences in model speciﬁcations, the overall results were similar
across the two models, and were consistent with results of a
previous modeling study (24).
The breast cancer model demonstrated that in the absence of a
precursor lesion, early detection is key and time to diagnostic
testing can have a large impact on screening effectiveness. The
cervical cancer model demonstrated that the screening regimens
are more robust when the disease trajectory is long and precursor
lesions may regress.
Although we predicted that longer times to diagnostic testing
couldmeaningfully worsen the efﬁcacy of breast cancer screening,
the times to testing we simulated are not common in clinical
practice; diagnostic testing generally occurs within weeks of a
screening mammography suggestive of a malignancy (i.e.,
BI-RADS 4 or 5; ref. 3). This is likely due to the federal
MammographyQuality Standards Act (25), which regulates time-
ly reporting of mammography screening results in plain language
(26). Our simulation study supports the rapid follow-up of
abnormal mammograms, but also highlights trade-offs that are
inherent to breast cancer screening. Because some DCIS is indo-
lent, screening could result in detection and treatment of cancers
thatwouldhave causednoharm.Although shorter time to follow-
up resulted in more DCIS, we do not assume that diagnosis of
DCIS constitutes overdiagnosis. Other collaborative modeling
analyses of screening programs have shown that overdiagnosis
rates are relatively insensitive to screening frequency (27), indi-
cating that relatively short delays in diagnosis do not affect overall
rates of overdiagnosis. This is consistent with our ﬁndings that the
overall breast cancer incidence didnot varywith time todiagnosis.
Longer time to diagnostic evaluation of abnormal tests reduces
the effectiveness and therefore the cost-effectiveness of screening.
Our ﬁndings are important in light of existing policy and recent
ﬁndings describing variation in time to follow-up of positive
screening tests (3, 28). Federal policies regulating breast cancer
screening encourage timely result reporting, which may facilitate
timely follow-up. There are no such regulations for either cervical
or colorectal cancer screening. Instead, the quality of cervical and
colorectal cancer screening is largely monitored voluntarily,
through reporting of Healthcare Effectiveness Data and Informa-
tion Set (HEDIS) measures, which focus on receipt of screening
tests, but not follow-up of abnormal screening (29). Our analyses
suggest that newpolicies focusedon timeliness of follow-up could
improve the effectiveness of colorectal cancer screening, in par-
ticular (30). Further research examining the barriers to diagnostic
testing at both the individual and health system level can help
inform strategies for improved follow-up of positive tests. For
example, diagnostic assessment of positive abnormal screening
results (via colonoscopy) is improved when healthcare systems
directly notify gastroenterology providers about referral for fol-
low-up (31).
It is important to keep inmind the limitations of our work. Our
results are based on simulation modeling, which requires
assumptions about disease processes, health practices, and
patient behaviors. Dwell time and disease progression during the
preclinical detectable period drive screening effectiveness and the
impact of delays on screening outcomes (32). However, dwell
time assumptions that are built into simulationmodels cannot be
changed in isolation because models incorporate multiple
assumptions that work together. Model calibrationmodiﬁes each
of these assumptions, via parameter selection, so that models
produce plausible simulated outcomes. When assumptions can-
not easily bemodiﬁed, cross-model comparisons provide the best
insight into the relationships between different disease assump-
tions and simulated outcomes. For example, as previously noted,
the two CRC models make fairly different assumptions about
dwell time, yet predict similar effects of delays in follow-up on
mortality. The MISCANmodeling group examined the sensitivity
of theirmodel's results to assumptions about dwell time,ﬁnding a
larger effect of time to follow up on CRC mortality when average
dwell timewas halved (24). TheHarvard cervical cancermodeling
group has carried out probabilistic sensitivity analysis based on a
sample of 50 calibratednatural history parameter sets that vary the
model assumptions related to transitions among HPV and CIN
states (33). These sensitivity analyses show that the cervical cancer
model predictions of screening beneﬁt are stable over this set of
parameters across a range of different screening intervals (12),
suggesting that underlying assumptions would have relatively
little impact on predicted model outcomes. The impact of dwell
time assumptions may be different for breast cancer models than
for CRC or cervical cancer models because breast cancer does not
have an identiﬁed precursor lesion. Cross-model comparisons
found that the Wisconsin breast cancer model (included in this
paper) predicted greater beneﬁts from increased screening fre-
quency than four other breast cancer models, suggesting that the
estimates we present provide an upper bound on the effects of
delayed breast cancer diagnosis (27).
Our analyses did not examine risk factors or patient character-
istics that might impact the effect of delays on outcomes. For
example, we did not examine whether delays may vary based on
age, which is related to the underlying risk of cancer.
Use ofmodels allowed us to extend existing evidence to address
questions about the impact of time to diagnostic testing on long-
term cancer outcomes. Although each of the models used in our
analysis iswell established, there is no guarantee of the accuracy of
model assumptions, especially for parameters representing unob-
servable processes such as tumor growth and for predictions over
longer periods. Our results could be strengthened by ﬁndings
from other simulation studies or, potentially, large-scale obser-
vational studies that examine the effect of time to follow-up on
shorter-term cancer outcomes.
In conclusion, our study demonstrates that relatively small
delays in diagnostic follow-up of abnormal ﬁndings could reduce
cancer screening effectiveness, although the impact varies by
cancer type. This suggests that there is value in efforts to promptly
perform follow-up of positive test results, either within individual
health care systems or through federal policies related to regula-
tion and reporting. In addition to improving the overall
effectiveness of screening, reducing time to follow-up has the
potential to reduce health disparities in patients who are more
likely to experience delays and improve patient quality of life by
avoiding systemic treatment. Reducing time to follow-up may
also prove to be cost-effective by avoiding the need for expensive
treatment regimens.
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